Medical Disclaimer: This site provides informational comparisons only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician or pharmacist before making medication decisions.
Compare UPADACITINIB (Rinvoq) and Vedolizumab (Entyvio) — clinical data, side effects, and patient experiences.
Rinvoq · JAK Inhibitor
How it works
12.1 Mechanism of Action Upadacitinib is a Janus kinase (JAK) inhibitor. JAKs are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor inter...
Approved for
Entyvio · Integrin Inhibitor
How it works
Humanized monoclonal antibody that binds alpha4-beta7 integrin, blocking lymphocyte trafficking to gut-associated lymphoid tissue.
Approved for
Estimated frequency (%) based on clinical trial data
Based on 15 Reddit discussions
UPADACITINIB
60%
positive
15 threads
Vedolizumab
0%
positive
0 threads
% of discussions mentioning each side effect
15 Reddit threads analysed for UPADACITINIB
Overall Sentiment
Slightly positive
Comparison Threads
0
Avg Post Score
29 upvotes
Most discussed side effects in community
For context: for pretty much all of last year over 80% of my body was covered in eczema rash. It was so severe I couldn't use the shower and had to either take baths or wash myself in the sink. My scalp was constantly peeling and I was *always* itchy. While my skin would get better in summer, it was
#Earnings Advance Auto Parts (AAP) Q4 Adj. EPS USD 1.17 vs. Exp. USD 1.13, revenue USD 2.1bln vs. Exp. USD 2.11bln, SSS increased by 3.4%. Sees FY19 revenue USD 9.65bln-9.8bln vs. Exp. USD 9.78bln. (Newswires) Continental Resources (CLR) Q4 Adj. EPS USD 0.54 vs. Exp. USD 0.62, revenue USD 1.15
Hey everyone! I just wanted to provide some sort of update having been on Upadacitinib for just over a month. My eczema is gone and I no longer need to take cold showers and I don't even need to moisturise after showers. My skin looks healthy and clear it is so surreal. This medication is not a ste
Welcome back to this week's newsflash 1. Vedolizumab, a medication used for ulcerative colitis, shows promise in treating chronic pouchitis as well. A new study found it to be effective in reducing ulcer count and inducing mucosal healing. Do you want to know [more](https://www.healio.com/news/gastr
I am interested in participating in a clinical trial. I am leaning towards the 3 mentioned in the title, though I would love to hear about any others that seem promising. I am hoping there will be phase 3 trials in my area some time in the first half of 2018 for ABT-494 and PF-04965842. Phase 3 for
About 80% of my body was covered when I went to the dermatologist, so he sent me to hospital for inpatient treatment for 5 days. I did a paraffin bath -> topical steroid -> wet wrap -> emollient treatment twice a day and everything has cleared up. I've been given a metric tonne of moisturiz
Almost a year ago, after years of worsening Atopic Dermatitis, i said enough is enough, and decided to buy Upadacitinib, a JAK inhibitor originally used for rheumatoid arthritis, after reading about very promising clinical trials for AD. When i posted about it many of you guys were surprised about
Community discussions are sourced from public Reddit threads. Content reflects individual opinions and is not medical advice.
No community discussions found for Vedolizumab yet.
UPADACITINIB is a JAK Inhibitor, while Vedolizumab belongs to the Integrin Inhibitor class. This means they work through different pharmacological mechanisms, which may influence both efficacy and side effect profiles. UPADACITINIB is administered via Oral, whereas Vedolizumab uses Intravenous or Subcutaneous. Route of administration can affect onset of action and patient adherence.
UPADACITINIB carries 4 FDA warnings. Vedolizumab carries 3 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..
This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.